Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104

Clinical Cancer Research

Volumn 13, Issue 13, 2007, Pages 3922-3932

  Patterson, Adam V ^a   Ferry, Dianne M ^a   Edmunds, Shelley J ^a   Gu, Yongchuan ^a   Singleton, Rachelle S ^a   Patel, Kashyap ^a   Pullen, Susan M ^a   Hicks, Kevin O ^a   Syddall, Sophie P ^a   Atwell, Graham J ^a   Yang, Shangjin ^a   Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 [(2 BROMOETHYL) 2 [[(2 HYDROXYETHYL)AMINO]CARBONYL] 4,6 DINITROANILINO]ETHYL METHANESULFONATE PHOSPHATE ESTER; CHLORAMBUCIL; CHLORIDE ION; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DRUG METABOLITE; GEMCITABINE; HISTONE H2AX; HYDROXYLAMINE; MELPHALAN; ORGANOPHOSPHATE; PR 104; PR 104A; PR 104H; PRODRUG; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DNA DAMAGE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; IN VITRO STUDY; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLITE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMET ASSAY; CROSS-LINKING REAGENTS; DNA; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONES; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; PHOSPHATES;

EID: 34447122556     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0478     Document Type: Article

References (50)

1. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
2. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
3. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20:237-50.
4. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
5. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634-9.
6. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2α and carbonic anhydrase 9) are associated with radiotherapy failure inhead and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-35.
7. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
8. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.
9. Hicks KO, Pruijn FB, Secomb TW, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006;98:1118-28.
10. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
11. Vaupel P, Kelleher DK, editors. Tumor hypoxia: pathophysiology, clinical significance and therapeutic perspectives. Stuttgart (Germany): Wissenschaftliche Verlagsgesellschaft mbH; 1999.
12. Haffty BG, Wilson LD, Son YH, et al. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 2005;61:119-28.
13. Cole S, Stratford IJ, Fielden EM, et al. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908). Int J Radiat Oncol Biol Phys 1992;22:545-8.
14. Breider MA, Pilcher GD, Graziano MJ, Gough AW. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol 1998;26:234-9.
15. Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 2000;163:50-9.
16. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02). J Clin Oncol 2005;23:79-87.
17. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000;83:1589-93.
18. Helsby NA, Wheeler SJ, Pruijn FB, et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol 2003;16:469-78.
19. Palmer BD, Wilson WR, Anderson RF, Boyd M, Denny WA. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4- dinitrobenzamide. J Med Chem 1996;39:2518-28.
20. Siim BG, Denny WA, Wilson WR. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol Res 1997;9:357-69.
21. Wilson WR, Hicks KO, Pullen SM, et al. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 2007;167:625-36.
22. Wilson WR, Pullen SM, Hogg A, et al. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 2002;62:1425-32.
23. Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitro-reductase GDEPT. Br J Cancer 2004;90:1084-93.
24. Denny WA, Atwell GJ, Yang S, et al., inventors; Auckland Uniservices Ltd., assignee. Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents. PCT WO 2005042471A1. 2005.
25. Hay MP, Gamage SA, Kovacs MS, et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 2003;46:169-82.
26. Atwell GJ, Denny WA. Synthesis of 3H- and 2H4-labelled versions of the hypoxia-activated pre-pro-drug 2-[(2-bromoethyl)-2,4-dinitro-6-[2-(phosphonooxy) ethyl]amino]carbonyl]anilino]ethylmethanesulfonate (PR-104). J Labelled Compounds Radiopharmaceuticals 2006;50:7-12.
27. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 2003;63:5970-7.
28. Tercel M, Lee AE, Hogg A, et al. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 2001;44:3511-22.
29. 1-phase cells. Radiat Res 2003;159:759-67.
30. Palmer BD, van Zijl P, Denny WA, Wilson WR. Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4- dinitrobenzamide. J Med Chem 1995;38:1229-41.
31. Thompson LH, Busch DB, Brookman K, Mooney CL, Glaser DA. Genetic diversity of UV-sensitive DNA repair mutants of Chinese hamster ovary cells. Proc Natl Acad Sci U S A 1981;78:3734-7.
32. Brookman KW, Lamerdin JE, Thelen MP, et al. ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs. Mol Cell Biol 1996;16:6553-62.
33. Olive PL, Banath JP, Durand RE. The range of oxygenation in SiHa tumor xenografts. Radiat Res 2002;158:159-66.
34. Bennewith KL, Durand RE. Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 2004;64:6183-9.
35. Huxham LA, Kyle AH, Baker JHE, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004;63:6537-41.
36. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-84.
37. Jang SH, Wientjes MG, Au JL. Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs 2001;19:113-23.
38. Denny WA, Wilson WR. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem 1986;29:879-87.
39. Monks NR, Blakey DC, East SJ, et al. DNA inter-strand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767. Eur J Cancer 2002;38:1543-52.
40. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003;63:4347-50.
41. Song BL, Wang Q, Du Y, et al. The in vivo selection of the R-enantiomer of KS119W (VNP40541) as a potential anticancer agent. Proc Am Assoc Cancer Res 2006;47:1108.
42. Seow HA, Penketh PG, Shyam K, Rockwell S, Sartorelli AC. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[1-(4-nitrophenyl)ethoxy]carbonyl] hydrazine: an anticancer agent targeting hypoxic cells. Proc Natl Acad Sci U S A 2005;102:9282-7.
43. Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000;6:1016-23.
44. Hardman WE, Moyer MP, Cameron IL. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res 1999;19:2269-74.
45. Kovacs MS, Hocking DJ, Evans JW, et al. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 1999;80:1245-51.
46. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 2003;9:5714-20.
47. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000;48:919-22.
48. Vaupel P, Thews O, Kelleher DK. Pancreatic tumors show high levels of hypoxia: regarding Koong, et al. IJROBP 2000;48:919-2. Int J Radiat Oncol Biol Phys 2001;50:1099-100.
49. Parker C, Milosevic M, Toi A, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750-7.
50. Carnell DM, Smith RE, Daley FM, et al. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 2006;65:91-9.